Bookmark Saya

DOAJ Open Access 2022

Anti-TNFα Treatment Impairs Long-Term Immune Responses to COVID-19 mRNA Vaccine in Patients with Inflammatory Bowel Diseases

Keren Masha Rabinowitz Michal Navon Hadar Edelman-Klapper Eran Zittan Ariella Bar-Gil Shitrit +37 lainnya
Lihat Sumber DOI

Abstrak

Patients with inflammatory bowel disease (IBD) treated with anti-tumor-necrosis factor-alpha (TNFα) exhibited lower serologic responses one-month following the second dose of the COVID-19 BNT162b2 vaccine compared to those not treated with anti-TNFα (non-anti-TNFα) or to healthy controls (HCs). We comprehensively analyzed long-term humoral responses, including anti-spike (S) antibodies, serum inhibition, neutralization, cross-reactivity and circulating B cell six months post BNT162b2, in patients with IBD stratified by therapy compared to HCs. Subjects enrolled in a prospective, controlled, multi-center Israeli study received two BNT162b2 doses. Anti-S levels, functional activity, specific B cells, antigen cross-reactivity, anti-nucleocapsid levels, adverse events and IBD disease score were detected longitudinally. In total, 240 subjects, 151 with IBD (94 not treated with anti-TNFα and 57 treated with anti-TNFα) and 89 HCs participated. Six months after vaccination, patients with IBD treated with anti-TNFα had significantly impaired BNT162b2 responses, specifically, more seronegativity, decreased specific circulating B cells and cross-reactivity compared to patients untreated with anti-TNFα. Importantly, all seronegative subjects were patients with IBD; of those, >90% were treated with anti-TNFα. Finally, IBD activity was unaffected by BNT162b2. Altogether these data support the earlier booster dose administration in these patients.

Topik & Kata Kunci

Medicine

Penulis (42)

K

Keren Masha Rabinowitz

M

Michal Navon

H

Hadar Edelman-Klapper

E

Eran Zittan

A

Ariella Bar-Gil Shitrit

I

Idan Goren

I

Irit Avni-Biron

J

Jacob E. Ollech

L

Lev Lichtenstein

H

Hagar Banai-Eran

H

Henit Yanai

Y

Yifat Snir

M

Maor H. Pauker

A

Adi Friedenberg

A

Adva Levy-Barda

A

Arie Segal

Y

Yelena Broitman

E

Eran Maoz

B

Baruch Ovadia

M

Maya Aharoni Golan

E

Eyal Shachar

S

Shomron Ben-Horin

N

Nitsan Maharshak

M

Michal Mor

H

Haim Ben Zvi

R

Rami Eliakim

R

Revital Barkan

T

Tali Sharar-Fischler

S

Sophy Goren

N

Noy Krugliak

E

Edward Pichinuk

M

Michael Mor

M

Michal Werbner

J

Joel Alter

H

Hanan Abu-Taha

K

Kawsar Kaboub

M

Moshe Dessau

M

Meital Gal-Tanamy

D

Dani Cohen

N

Natalia T. Freund

I

Iris Dotan

o

on behalf of the Responses to COVID-19 Vaccine Israeli IBD Group

Format Sitasi

APA MLA BibTeX
Rabinowitz, K.M., Navon, M., Edelman-Klapper, H., Zittan, E., Shitrit, A.B., Goren, I. et al. (2022). Anti-TNFα Treatment Impairs Long-Term Immune Responses to COVID-19 mRNA Vaccine in Patients with Inflammatory Bowel Diseases. https://doi.org/10.3390/vaccines10081186

Akses Cepat

PDF tidak tersedia langsung

Cek di sumber asli →
Lihat di Sumber doi.org/10.3390/vaccines10081186
Informasi Jurnal
Tahun Terbit
2022
Sumber Database
DOAJ
DOI
10.3390/vaccines10081186
Akses
Open Access ✓